NewsBrooks Laboratories Informs Exchanges: Associate Firm Brooks Steriscience Limited Withdraws From Proposed Merger SchemeBrooks Laboratories Informs Exchanges: Associate Firm Brooks Steriscience Limited Withdraws From Proposed Merger Scheme
Brooks Laboratories Limited has notified the stock exchanges that Brooks Steriscience Limited (BSL), its joint venture and associate, has decided not to pursue the proposed composite scheme of arrangement and amalgamation in its current form. The decision was taken by BSL's Board of Directors at a meeting held on May 14, 2026, in the best interest of all stakeholders. The proposed scheme had earlier received in-principle approval from the National Stock Exchange of India Limited and BSE Limited on February 6, 2026, and involved a merger by absorption among five entities including Onesource Specialty Pharma Limited. The disclosure was made under Regulation 30 by Company Secretary Krutika Rane.
*this image is generated using AI for illustrative purposes only.
In a regulatory filing dated May 14, 2026, brooks laboratories disclosed that Brooks Steriscience Limited (BSL), a joint venture and associate of the company, has opted not to proceed with a previously announced composite scheme of arrangement and amalgamation. The decision was reached at a meeting of BSL's Board of Directors held on the same date, with the board citing the best interest of all stakeholders as the basis for withdrawing from the transaction in its current form.
Background of the Proposed Scheme
The development is a follow-up to an earlier intimation issued on February 6, 2026, which had detailed the in-principle approval granted by the National Stock Exchange of India Limited and BSE Limited to Onesource Specialty Pharma Limited for the proposed composite scheme. The scheme had envisaged a merger by absorption involving multiple entities, as outlined below:
| Parameter: | Details |
|---|---|
| Type of Transaction: | Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) |
| Entities Involved: | Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource Specialty Pharma Limited |
| In-Principle Approval Date: | February 6, 2026 |
| Approving Exchanges: | National Stock Exchange of India Limited and BSE Limited |
| Board Decision Date: | May 14, 2026 |
| Decision: | Not to pursue the transaction in the current form |
Board Decision and Stakeholder Considerations
BSL's Board of Directors, after deliberating on the proposed transaction at its meeting on May 14, 2026, resolved not to proceed with the scheme in its current form. The board's decision was communicated to Brooks Laboratories, which subsequently notified the stock exchanges in compliance with applicable disclosure requirements. The filing was signed by Krutika Rane, Company Secretary and Compliance Officer of Brooks Laboratories Limited, bearing Membership No. 66310.
Regulatory Disclosure
The intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited as part of the company's obligations under Regulation 30. Brooks Laboratories has requested the exchanges to take the update on record. No further details regarding the reasons for the withdrawal or any revised transaction structure were provided in the filing.
Historical Stock Returns for Brooks Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +31.87% | +1.29% | -37.60% | -50.60% | -38.63% |
Will BSL and the other entities involved explore a revised merger structure, and what key changes might be necessary to make a future scheme viable for all stakeholders?
How might the withdrawal of this amalgamation scheme impact Brooks Laboratories' long-term strategic positioning and its stake valuation in BSL as an associate company?
Could Onesource Specialty Pharma Limited pursue alternative consolidation strategies with other pharma entities following BSL's exit from the proposed scheme?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
